-
公开(公告)号：US20250019374A1
公开(公告)日：2025-01-16
申请号：US18709214
申请日：2022-11-10
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Andrew Bogdan , Elliot P. Farney , Jennifer M. Frost , Philip R. Kym , Zhaoming Xiong , Naomi Anne Barton , Claire Anne Marie Cariou-Mumford , Christopher Patrick McMahon , Giuseppe Nano
IPC: C07D417/04 , A61K31/433 , A61K31/454 , C07D417/14
Abstract: The present invention provides for compounds of Formula (I) (I); wherein R2, X, and Z have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.
-
公开(公告)号：US20240024338A1
公开(公告)日：2024-01-25
申请号：US18334738
申请日：2023-06-14
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao. , Xiaochun Lou , Sean Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff G. Zhang
CPC classification number: A61K31/661 , A61K9/0019 , A61K9/14 , A61K45/06 , A61K9/08 , C07F9/12
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US20130345255A1
公开(公告)日：2013-12-26
申请号：US13922442
申请日：2013-06-20
Applicant: AbbVie Inc.
Inventor： Arthur Gomtsyan , Jerome Daanen , Michael E. Kort , Philip R. Kym , Eric A. Voight , Kevin R. Woller
IPC: C07C317/28 , A61K31/192 , A61K31/353 , A61K31/436 , A61K31/352 , C07D311/96 , C07D491/052 , A61K31/18 , C07D311/68
CPC classification number: C07C317/28 , A61K31/18 , A61K31/192 , A61K31/352 , A61K31/353 , A61K31/436 , C07C311/08 , C07C2602/08 , C07D263/48 , C07D311/68 , C07D311/96 , C07D401/04 , C07D417/12 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，前药或其组合，其中X1，L，Rx，Ry，Rz，R1，R2，A，m，n，p，q和r定义在 规格。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20250042894A1
公开(公告)日：2025-02-06
申请号：US18709204
申请日：2022-11-10
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Andrew Bogdan , Christos Economou , Jennifer M. Frost , Philip R. Kym , Spencer O. Scholz , Zhaoming Xiong
IPC: C07D417/14 , A61K31/433 , C07D417/04
Abstract: The present invention provides for compounds of Formula (I) wherein R1, has any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.
-
公开(公告)号：US20220153765A1
公开(公告)日：2022-05-19
申请号：US17378321
申请日：2021-07-16
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff G. Zhang
IPC: C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
Patent Agency Ranking
公开(公告)号：US10730895B2
公开(公告)日：2020-08-04
申请号：US16210996
申请日：2018-12-05
Applicant: AbbVie Inc.
Inventor： Philip R. Kym , Eric A. Voight
IPC: C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US20190375770A1
公开(公告)日：2019-12-12
申请号：US16210996
申请日：2018-12-05
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christiopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff G. Zhang
IPC: C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US20180243298A1
公开(公告)日：2018-08-30
申请号：US15563888
申请日：2016-03-30
Applicant: AbbVie Inc.
Inventor： Lawrence Black , Brian S. Brown , Bruce Clapham , Marlon D. Cowart , Michael J. Dart , Ramin Faghih , Jennifer Frost , Arthur R. Gomtsyan , Philip R. Kym , Huaqing Liu , Robert G. Schmidt , Lei Shi , Anurupa Shrestha , Kevin Sippy
IPC: A61K31/506 , A61P17/06 , A61P17/04
CPC classification number: A61K31/506 , A61P17/04 , A61P17/06 , C07D417/12 , C07D417/14 , C07D491/048 , C07D491/107
Abstract: A compound of Formula (I) having efficacy for the treatment or prevention of conditions and disorders related to TRPV3 activity, e.g. pain, atopic dermatitis, eczema, itch or psoriasis, is disclosed. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
-
公开(公告)号：US20160120841A1
公开(公告)日：2016-05-05
申请号：US14925649
申请日：2015-10-28
Applicant: AbbVie Inc.
Inventor： Philip R. Kym , Xueqing Wang , Xenia B. Searle , Bo Liu , Ming C. Yeung , Robert J. Altenbach , Eric Voight , Andrew Bogdan , John R. Koenig
IPC: A61K31/353 , A61K45/06 , C07D405/14 , A61K31/4433 , C07D491/052 , A61K31/435 , A61K31/4025 , A61K31/453 , C07D413/14 , A61K31/5377 , A61K31/397 , C07D491/107 , C07D407/12 , A61K31/436
CPC classification number: C07D407/12 , A61K31/00 , A61K31/353 , A61K31/397 , A61K31/4025 , A61K31/435 , A61K31/436 , A61K31/4433 , A61K31/453 , A61K31/5377 , A61K45/06 , C07D405/14 , C07D413/14 , C07D491/052 , C07D491/107 , A61K2300/00
Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
Abstract translation: 本发明提供式（I）化合物，其中R1，X，Y，R4，R5，R6，R7，R8，R9，R10，R11，R12，R13，R14，m和R“具有定义的任何值 在本说明书及其药学上可接受的盐中，其可用作治疗由CFTR介导和调节的疾病和病症的药剂，包括囊性纤维化，Siegren综合征，胰腺功能不全，慢性阻塞性肺病和慢性阻塞性气道疾病。 还提供了由一种或多种式（I）化合物组成的药物组合物。
-
公开(公告)号：US09156788B2
公开(公告)日：2015-10-13
申请号：US13761862
申请日：2013-02-07
Applicant: AbbVie Inc.
Inventor： Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Eric A. Voight
IPC: A61K31/444 , C07D213/30 , C07D239/26 , C07D401/04 , C07D405/12 , C07D213/50 , C07D401/12
CPC classification number: C07D213/30 , C07D213/50 , C07D239/26 , C07D401/12 , C07D405/12
Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式（I）的TRPV3的调节剂，其中G1，X1，X2，X3，X4，X5，G2，Z1，Ra，Rb，u和p如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.034 seconds)
